Clay Siegall is passionate about cancer research and through his company- Seattle Genetics he has managed to make tremendous changes in the field of research.
Seattle Genetics has been involved in cancer therapy research for almost two decades. They have established themselves as leaders in the industry through the different research they have done. The Company has achieved significant success in the sector considering that their stock price has tripled in the last five years.
Clay Siegall has been the Chief Executive Officer of the Company since 2002 and has led the company to do ground-breaking research in Cancer Therapies. He also guided them to developing an antibody- drug conjugates and they secured the FDA approval in 2011 for ADCETRIS.
In partnership with the Takeda Pharmaceuticals Company, the antibody has become a global brand present in over 65 countries. Clay has also led the Company to enter into different licenses for its technology including GlaxoSmithKline, AbbVie, Pfizer and Genentech. There are over 20 clinical developments that are using the ADC technology. He has been able to secure both private and public financing generating over $1.2 billion.
He is the co-founder of Seattle Genetics, established in 1998 and he serves as the President and also the Chairman of the Board. Clay Siegall founded the Company to provide scientific innovation and research.
Before co-founding the Seattle Genetics, Clay was working for the Bristol Meyers Squibb Pharmaceutical Research Institute. Between 1988 and 1991 he was with the National Cancer Institute. He serves on the Board of Directors of different companies including Ultragenyx Pharmaceuticals, Washington Roundtable and Alder BioPharmaceuticals.
He has received different awards in the course of his career including the 2013 Maryland Alumnus of the Year for Computer, Math and Natural Sciences. He was also the recipient of the Pacific Northwest Ernst & Young Entrepreneur of the Year in 2012.
He holds a Bachelor of Science Degree in Zoology from the University of Maryland and a PhD in Genetics from George Washington University. Clay Siegall is also an author and has published more than 70 research articles and holds 15 patents.